LCTX Stock Analysis: Buy, Sell, or Hold?
LCTX - Lineage Cell Therapeutics, Inc.
$1.11
-0.05 (-4.31%)
▼
5d:
+2.78%
30d:
+0.0%
90d:
-16.54%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When LCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: LCTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: LCTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: LCTX is currently trading at $1.11, which is considered extended relative to its 30-day fair value range of $1.06 to $1.13.
Technical Outlook: Technically, LCTX is in a strong downtrend. Immediate support is located at $1.04, while resistance sits at $1.19. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: LCTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.50 (+395.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LCTX is in a strong downtrend. Immediate support is located at $1.04, while resistance sits at $1.19. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: LCTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.50 (+395.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.06 -
$1.13
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 395.5% below Wall St target ($5.50)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.06 -
$1.13
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.04
Resistance Level
$1.19
Current Trend
Strong Downtrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.88
Wall Street Target
$5.50
(+395.5%)
Revenue Growth (YoY)
-61.3%
Profit Margin
-246.6%
Share & Embed Analysis
Last updated: August 29, 2026 3:02 AM ET
Data refreshes hourly during market hours. Next update: 4:02 AM
Data refreshes hourly during market hours. Next update: 4:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LCTX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Brian M Culley
BUY
15000 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 42 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 38 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 40 SELL |
